- Home
- ERAS vs SCM Comparison
ERAS vs SCM Comparison
Compare ERAS & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- SCM
- Stock Information
- Founded
- ERAS 2018
- SCM 2012
- Country
- ERAS United States
- SCM United States
- Employees
- ERAS N/A
- SCM N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- SCM Finance/Investors Services
- Sector
- ERAS Health Care
- SCM Finance
- Exchange
- ERAS Nasdaq
- SCM Nasdaq
- Market Cap
- ERAS 439.7M
- SCM 397.8M
- IPO Year
- ERAS 2021
- SCM 2012
- Fundamental
- Price
- ERAS $2.86
- SCM $11.83
- Analyst Decision
- ERAS Buy
- SCM Hold
- Analyst Count
- ERAS 6
- SCM 1
- Target Price
- ERAS $3.50
- SCM $13.00
- AVG Volume (30 Days)
- ERAS 1.3M
- SCM 220.5K
- Earning Date
- ERAS 11-12-2025
- SCM 11-10-2025
- Dividend Yield
- ERAS N/A
- SCM 13.54%
- EPS Growth
- ERAS N/A
- SCM N/A
- EPS
- ERAS N/A
- SCM 1.09
- Revenue
- ERAS N/A
- SCM $102,538,895.00
- Revenue This Year
- ERAS N/A
- SCM N/A
- Revenue Next Year
- ERAS N/A
- SCM $1.23
- P/E Ratio
- ERAS N/A
- SCM $10.80
- Revenue Growth
- ERAS N/A
- SCM N/A
- 52 Week Low
- ERAS $1.01
- SCM $11.19
- 52 Week High
- ERAS $3.30
- SCM $15.56
- Technical
- Relative Strength Index (RSI)
- ERAS 69.19
- SCM 40.95
- Support Level
- ERAS $2.21
- SCM $11.81
- Resistance Level
- ERAS $2.90
- SCM $12.20
- Average True Range (ATR)
- ERAS 0.20
- SCM 0.29
- MACD
- ERAS 0.04
- SCM 0.04
- Stochastic Oscillator
- ERAS 96.19
- SCM 43.76
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About SCM Stellus Capital Investment Corporation
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.